Crossmark Global Holdings Inc. Has $6.62 Million Stock Holdings in MetLife, Inc. $MET

Crossmark Global Holdings Inc. decreased its stake in shares of MetLife, Inc. (NYSE:MET) by 29.3% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 80,375 shares of the financial services provider’s stock after selling 33,306 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in MetLife were worth $6,620,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in MET. Salomon & Ludwin LLC grew its stake in shares of MetLife by 95.4% in the third quarter. Salomon & Ludwin LLC now owns 422 shares of the financial services provider’s stock valued at $35,000 after buying an additional 206 shares in the last quarter. True Wealth Design LLC raised its position in MetLife by 564.1% during the third quarter. True Wealth Design LLC now owns 425 shares of the financial services provider’s stock worth $35,000 after acquiring an additional 361 shares in the last quarter. Evolution Wealth Management Inc. bought a new stake in MetLife during the second quarter worth $35,000. MTM Investment Management LLC acquired a new stake in MetLife in the second quarter valued at $37,000. Finally, Dunhill Financial LLC grew its position in shares of MetLife by 413.2% in the 3rd quarter. Dunhill Financial LLC now owns 467 shares of the financial services provider’s stock valued at $38,000 after acquiring an additional 376 shares during the period. Institutional investors own 94.99% of the company’s stock.

More MetLife News

Here are the key news stories impacting MetLife this week:

• Positive Sentiment: MetLife confirmed its previously announced Q1 2026 dividend on its Series A floating-rate preferred shares, $0.31501229 per share, signaling consistency in capital returns for preferred holders and helping support yield-sensitive investors. Article Title
• Positive Sentiment: MetLife and partner Crow Holdings completed the sale/trade of 210 multifamily units in Tampa — an example of active portfolio management that can free capital or crystallize gains from real-estate holdings. Article Title
• Neutral Sentiment: MetLife GCC leased ~75,000 sq ft in Noida’s Oxygen Business Park — a regional expansion/lease that speaks to business presence in India but is unlikely to move the stock materially in the near term. Article Title
• Neutral Sentiment: High-profile events at MetLife Stadium (temporary renaming/World Cup hosting coverage, ticket guides) increase brand visibility and venue revenue potential, but these items are peripheral to core insurance fundamentals. Article Title
• Neutral Sentiment: A recent piece comparing MetLife’s stock performance to peers provides context for relative valuation and momentum; useful for investors but not a direct catalyst. Article Title
• Negative Sentiment: Morgan Stanley published a pessimistic forecast for MET, which likely contributed to selling pressure and the intraday decline — analyst downgrades/price-target cuts are common drivers of short-term stock weakness. Article Title

Analyst Ratings Changes

Several research analysts have recently weighed in on MET shares. UBS Group boosted their price objective on shares of MetLife from $94.00 to $98.00 and gave the stock a “buy” rating in a research note on Thursday, February 5th. Barclays set a $90.00 price target on MetLife in a report on Thursday, January 8th. Morgan Stanley lowered their price target on MetLife from $101.00 to $93.00 and set an “overweight” rating on the stock in a research report on Tuesday. Mizuho set a $100.00 price objective on MetLife in a research report on Thursday, February 12th. Finally, Wells Fargo & Company reduced their target price on MetLife from $97.00 to $93.00 and set an “overweight” rating for the company in a research note on Wednesday, February 25th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $94.18.

MetLife Stock Down 1.5%

Shares of NYSE MET opened at $71.83 on Friday. The stock has a market capitalization of $46.84 billion, a P/E ratio of 15.28, a PEG ratio of 0.67 and a beta of 0.76. The stock’s fifty day moving average is $77.20 and its 200 day moving average is $78.72. MetLife, Inc. has a 52 week low of $65.21 and a 52 week high of $85.00. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.20 and a current ratio of 0.20.

MetLife (NYSE:MET) last posted its quarterly earnings data on Wednesday, February 4th. The financial services provider reported $2.49 earnings per share for the quarter, topping the consensus estimate of $2.34 by $0.15. The business had revenue of $52.44 billion during the quarter, compared to analysts’ expectations of $31.43 billion. MetLife had a net margin of 4.38% and a return on equity of 21.81%. MetLife’s revenue was up 27.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.08 earnings per share. Sell-side analysts forecast that MetLife, Inc. will post 9.65 earnings per share for the current fiscal year.

MetLife Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 3rd will be issued a dividend of $0.5675 per share. This represents a $2.27 dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date of this dividend is Tuesday, February 3rd. MetLife’s dividend payout ratio is 48.30%.

About MetLife

MetLife, Inc is a global provider of insurance, annuities and employee benefit programs. Headquartered in New York City, the company offers a range of risk protection and retirement solutions to individuals, employers and institutional clients. Its core businesses include life insurance, group benefits, retirement products such as annuities, and supplemental health products including dental and disability coverage.

In addition to traditional life and group insurance, MetLife provides workplace benefits and voluntary products distributed through employer-sponsored programs.